Otonomy
Company

Last deal

$34.7M

Amount

Post-IPO Equity

Stage

07.04.2021

Date

3

all rounds

$498.01M

Total amount

date founded

Financing round

General

About Company
Otonomy is a biopharmaceutical company that develops and commercializes treatments for diseases of the inner and middle ear.

Industry

Sector :

Subsector :

founded date

01.01.2008

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

Their proprietary formulation platform provides sustained drug exposure from a single administration, which is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss, and tinnitus. The company's products include OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients, OTO-104, a sustained-exposure formulation of the steroid dexamethasone for the treatment of Meniere's disease and other inner ear conditions, and OTO-311, a sustained-exposure formulation for the treatment of tinnitus.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Strongbridge Biopharma

Strongbridge Biopharma

Strongbridge Biopharma is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Dublin, Ireland

total rounds

7

total raised

$196.5M
Aurinia Pharmaceuticals

Aurinia Pharmaceuticals

Aurinia Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapies for serious diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Biotechnology, Medical

Location

Victoria, BC, Canada

total rounds

7

total raised

$658.46M
Cotherix

Cotherix

CoTherix develops biopharmaceutical products for chronic diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Francisco, CA, USA

total rounds

2

total raised

$55M
Palatin Technologies

Palatin Technologies

Palatin is a biopharmaceutical company developing medicines that target the melanocortin peptide receptor system.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cranbury, NJ, USA

total rounds

9

total raised

$133.9M

Financials

Funding Rounds
10
3

Number of Funding Rounds

$498.01M

Money Raised

Their latest funding was raised on 07.04.2021. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
07.04.2021
$34.7M
09.07.2020
$69.1M
01.08.2019
$40M
Co-Investors
Investors
10
6

Number of lead investors

10

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Series D
Yes
Series D
OrbiMed

OrbiMed

OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Venture Capital, Health Care

Location

New York, NY, USA

count Of Investments

561

count Of Exists

82
Chau Khuong

Chau Khuong

Chau Q. Khuong joined OrbiMed Advisors in 2003 and is a Partner on the Private Equity team. Chau Khuong has experience in start-up operations and business development at Veritas Medicine, Inc. and in basic science research at the Yale School of Medicine and at Massachusetts General Hospital. He was a summer Associate in the New Ventures technology transfer group at Columbia University. At OrbiMed, Chau Khuong was actively involved investments in Arius Research, Inc. (acquired by Roche in 2008), Peninsula Pharmaceuticals, Inc. (acquired by Johnson & Johnson, Inc., in 2005), Cerexa, Inc. (acquired by Forest Laboratories, Inc., in 2007), Adiana, Inc. (acquired by Cytyc Corporation in 2007), Avanir (NASDAQ: AVNR), and Biodel, Inc. (NASDAQ: BIOD). He currently serves as Director or Observer on the Corporate Boards at Cerapedics, Glaukos Corporation, Intercept Pharma, Sonendo, and Pieris AG. Chau Khuong holds a BS in molecular biology with concentration in biotechnology and an MPH with concentration in infectious diseases, both from Yale University.

current job

OrbiMed
OrbiMed

count Of Investments

1
Jennison Associates

Jennison Associates

Jennison Associates is a wealth management firm that has been fulfilling client investment needs since 1969.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Finance, Wealth Management

Location

New York, NY, USA

count Of Investments

24

count Of Exists

5
Perceptive Advisors

Perceptive Advisors

Perceptive Advisors is a privately owned hedge fund sponsor that finances global public equity markets.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Finance, Venture Capital

Location

New York, NY, USA

count Of Investments

256

count Of Exists

20

People

Founders
2
Jeffrey Harris
Jeffrey Harris

Jeffrey Harris

Jeffrey Harris, M.D., Ph.D. is a Co-Founder of Otonomy, Inc. Dr. Harris serves as Professor and Chief of the Division of Otolaryngology-Head & Neck Surgery at the University of California, San Diego. A neuro-otologic surgeon who deals with disorders of the ear, hearing and balance, and tumors which affect the skull base. Dr. Harris serves as a Director and Member of Advisory Panel of Otonomy, Inc. He is past President of both the American Otological Society and the Association for Research in Otolarygology and is a Member of the Collegium Oto-Rhino-Laryngologicum Amicitiae Sacrum. Dr. Harris has an active clinical practice and leads a large research team committed to discovering the causes of deafness and other disorders such as acoustic neuromas, Meniere's disease, autoimmune inner ear disease and the effect of inflammation on inner ear structures. He has published over 150 scientific papers and 4 books including one on Meniere's Disease and his latest on the Head and Neck Manifestations of Systemic Disease. Dr. Harris obtained both his MD and PhD at the University of Pennsylvania and performed his otolaryngology residency training at Harvard. He did advanced fellowship training in Neurotology and Skull Base Surgery at the University of Zurich, and holds two board certifications, in both otolaryngology and neurotology/skull base surgery.

current job

Otonomy
Otonomy

organization founded

1

Jeffrey Harris

Jay Lichter
Jay Lichter

Jay Lichter

Jay Lichter is the Managing Director of Avalon Ventures and he was also the CEO of Sitari Pharmaceuticals. Dr. Lichter received a doctorate and bachelor’s degree in biochemistry from the University of Illinois. He also completed post-doctoral fellowships at Yale University and Du Pont Merck Pharmaceutical Company.

current job

Avalon Ventures
Avalon Ventures

Jay Lichter

Employee Profiles
32
Anna Stepanenko

Anna Stepanenko

Vice President, Technical Operations

David Skarinsky

David Skarinsky

Vice President, Clinical

Dragos Gherase

Senior scientist

Jeff Anderson

Senior director, clinical sciences

Martha Pastuszka

Scientist

Carla Boren

Carla Boren

General Counsel and Chief Human Resources Officer

Adrienne Terrazas

Executive assistant to chief executive officer and chief financial officer and general counsel

Alan Foster

Alan Foster

Vice President, Research

Activity

Recent News
0